AAAAAA
Results:
1-25
|
Results: 25
Authors:
Motzer, RJ
Rakhit, A
Thompson, JA
Nemunaitis, J
Murphy, BA
Ellerhorst, J
Schwartz, LH
Berg, WJ
Bukowski, RM
Citation: Rj. Motzer et al., Randomized multicenter phase II trial of subcutaneous recombinant human interleukin-12 versus interferon-alpha 2a for patients with advanced renal cell carcinoma, J INTERF CY, 21(4), 2001, pp. 257-263
Authors:
Mazumdar, M
Bajorin, DF
Bacik, J
Higgins, G
Motzer, RJ
Bosl, GJ
Citation: M. Mazumdar et al., Predicting outcome to chemotherapy in patients with germ cell tumors: The value of the rate of decline of human chorionic gonadotrophin and alpha-fetoprotein during therapy, J CL ONCOL, 19(9), 2001, pp. 2534-2541
Authors:
Motzer, RJ
Rakhit, A
Ginsberg, M
Rittweger, K
Vuky, J
Yu, R
Fettner, S
Hooftman, L
Citation: Rj. Motzer et al., Phase I trial of 40-kd branched pegylated interferon alfa-2a for patients with advanced renal cell carcinoma, J CL ONCOL, 19(5), 2001, pp. 1312-1319
Authors:
Vuky, J
Bains, M
Bacik, J
Higgins, G
Bajorin, DF
Mazumdar, M
Bosl, GJ
Motzer, RJ
Citation: J. Vuky et al., Role of postchemotherapy adjunctive surgery in the management of patients with nonseminoma arising from the mediastinum, J CL ONCOL, 19(3), 2001, pp. 682-688
Authors:
Berg, WJ
Schwartz, L
Yu, R
Mazumdar, M
Motzer, RJ
Citation: Wj. Berg et al., Phase II trial of irofulven (6-hydroxymethylacylfulvene) for patients withadvanced renal cell carcinoma, INV NEW DR, 19(4), 2001, pp. 317-320
Authors:
Kattan, MW
Reuter, V
Motzer, RJ
Katz, J
Russo, P
Citation: Mw. Kattan et al., A postoperative prognostic nomogram for renal cell carcinoma, J UROL, 166(1), 2001, pp. 63-67
Authors:
Mazumdar, M
Smith, A
Tong, WP
Motzer, RJ
Citation: M. Mazumdar et al., Calvert's formula for dosing carboplatin: Overview and concerns of applicability in high-dose setting, J NAT CANC, 92(17), 2000, pp. 1434-1436
Authors:
Vuky, J
Motzer, RJ
Citation: J. Vuky et Rj. Motzer, Cytokine therapy in renal cell cancer, UROL ONCOL, 5(6), 2000, pp. 249-257
Authors:
McCaffrey, JA
Reuter, V
Herr, HW
Macapinlac, HA
Russo, P
Motzer, RJ
Citation: Ja. Mccaffrey et al., Carcinoid tumor of the kidney - The use of somatostatin receptor scintigraphy in diagnosis and management, UROL ONCOL, 5(3), 2000, pp. 108-111
Authors:
Motzer, RJ
Citation: Rj. Motzer, High-dose chemotherapy in poor-risk germ-cell tumors, ONCOLOGY-NY, 14(10), 2000, pp. 1430
Authors:
Wolchok, JD
Motzer, RJ
Citation: Jd. Wolchok et Rj. Motzer, Management of renal cell carcinoma, ONCOLOGY-NY, 14(1), 2000, pp. 29
Authors:
Rabbani, F
Sheinfeld, J
Farivar-Mohseni, H
Leon, A
Rentzepis, MJ
Reuter, VE
Herr, HW
McCaffrey, JA
Motzer, RJ
Bajorin, DF
Bosl, GJ
Citation: F. Rabbani et al., Low-volume nodal metastases detected at retroperitoneal lymphadenectomy for testicular cancer: Pattern and prognostic factors for relapse, J CL ONCOL, 19(7), 2000, pp. 2020-2025
Authors:
Motzer, RJ
Mazumdar, M
Bacik, J
Russo, P
Berg, WJ
Metz, EM
Citation: Rj. Motzer et al., Effect of cytokine therapy on survival for patients with advanced renal cell carcinoma, J CL ONCOL, 18(9), 2000, pp. 1928-1935
Authors:
Motzer, RJ
Mazumdar, M
Sheinfeld, J
Bajorin, DF
Macapinlac, HA
Bains, M
Reich, L
Flombaum, C
Mariani, T
Tong, WP
Bosl, GJ
Citation: Rj. Motzer et al., Sequential dose-intensive paclitaxel, ifosfamide, carboplatin, and etoposide salvage therapy for germ cell tumor patients, J CL ONCOL, 18(6), 2000, pp. 1173-1180
Authors:
Motzer, RJ
Murphy, BA
Bacik, J
Schwartz, LH
Nanus, DM
Mariani, T
Loehrer, P
Wilding, G
Fairclough, DL
Cella, D
Mazumdar, M
Citation: Rj. Motzer et al., Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acidfor patients with advanced renal cell carcinoma, J CL ONCOL, 18(16), 2000, pp. 2972-2980
Authors:
Motzer, RJ
Sheinfeld, J
Mazumdar, M
Bains, M
Mariani, T
Bacik, J
Bajorin, D
Bosl, GJ
Citation: Rj. Motzer et al., Paclitaxel, ifosfamide, and cisplatin second-line therapy for patients with relapsed testicular germ cell cancer, J CL ONCOL, 18(12), 2000, pp. 2413-2418
Authors:
Vuky, J
McCaffrey, J
Ginsberg, M
Mariani, T
Bajorin, DF
Bosl, GJ
Motzer, RJ
Citation: J. Vuky et al., Phase II trial of pyrazoloacridine in patients with cisplatin-refractory germ cell tumors, INV NEW DR, 18(3), 2000, pp. 265-267
Authors:
Motzer, RJ
Citation: Rj. Motzer, Renal cell carcinoma: Progress against an elusive tumor, SEMIN ONCOL, 27(2), 2000, pp. 113-114
Authors:
Berg, WJ
Divgi, CR
Nanus, DM
Motzer, RJ
Citation: Wj. Berg et al., Novel investigative approaches for advanced renal cell carcinoma, SEMIN ONCOL, 27(2), 2000, pp. 234-239
Authors:
Motzer, RJ
Citation: Rj. Motzer, Paclitaxel (Taxol) combination therapy for resistant germ cell tumors, SEMIN ONCOL, 27(1), 2000, pp. 33-35
Authors:
Motzer, RJ
Russo, P
Citation: Rj. Motzer et P. Russo, Systemic therapy for renal cell carcinoma, J UROL, 163(2), 2000, pp. 408-417
Authors:
Motzer, RJ
Berg, WJ
Citation: Rj. Motzer et Wj. Berg, Role of interferon in metastatic renal cell carcinoma, CUR CLIN ON, 4, 2000, pp. 319-329
Authors:
Berg, WJ
Nanus, DM
Leung, A
Brown, KT
Hutchinson, B
Mazumdar, M
Xu, XC
Lotan, R
Reuter, VE
Motzer, RJ
Citation: Wj. Berg et al., Up-regulation of retinoic acid receptor beta expression in renal cancers in vivo correlates with response to 13-cis-retinoic acid and interferon-alpha-2a, CLIN CANC R, 5(7), 1999, pp. 1671-1675
Authors:
Motzer, RJ
Mazumdar, M
Bacik, J
Berg, W
Amsterdam, A
Ferrara, J
Citation: Rj. Motzer et al., Survival and prognostic stratification of 670 patients with advanced renalcell carcinoma, J CL ONCOL, 17(8), 1999, pp. 2530-2540
Authors:
Berg, WJ
McCaffrey, J
Schwartz, LH
Mariani, T
Mazumdar, M
Motzer, RJ
Citation: Wj. Berg et al., A phase II study of pyrazoloacridine in patients with advanced renal cell carcinoma, INV NEW DR, 16(4), 1998, pp. 337-340
Risultati:
1-25
|